ClinicalTrials.gg
RecruitingNCT04289142CODEXUpdated Dec 1, 2025

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

A Phase 4 interventional study of Dexmedetomidine Hydrochloride Group in Delirium, Cognitive Dysfunction and Cognition Disorder, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 8 sites in Canada. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Sunnybrook Health Sciences Centre · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Planned enrollment
Largest of 78
2,400 · median 98
Started
2019
with 7 others
Phase 4
35 of 78
5 open now
Primary completion
2028-07
later than 14 of 16 live
Registered
46th of 78
by date

Among the 78 studies testing dexmedetomidine in Delirium, this one has the largest planned enrollment, is one of 8 that started in 2019, is one of 35 in phase 4, reaches primary completion later than 14 of the 16 other live ones, and was the 46th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.

Read the detailed description

Dexmedetomidine (DEX), a highly potent and selective α2-adrenoceptors (α2R) agonist used in clinical practice for sedation, analgesia, and anxiolysis, was recently shown to have beneficial effects on early cognitive changes by reducing delirium in humans. It also reduced memory impairment after surgery and isoflurane anesthesia, both in elderly mice (20-22 months) and in pups exposed to anesthesia in the early postnatal period. Importantly, co-treatment with DEX has been shown to restore learning and memory function in rats exposed to propofol in utero. Therefore, the investigators set out to investigate whether DEX has an effect on cognitive dysfunction months after surgery and whether it accelerates cognitive recovery from anesthesia and surgery.

This is a double blinded, multi-site trial facilitated by Clinical Trials Ontario (CTO). Participants will be randomized 1:1 in permuted blocks of 4 to 8. The randomization sequence will be computer generated and stratified by 2 factors, planned procedure (CABG/CABG + valve or valve only procedure) and study site.

In hospital outcomes include delirium (assessed twice daily post-operative day (POD) 0-10, death, hemodynamic instability requiring vasopressors, time to extubation, re-intubation (and reason), length of stay (in Cardiovascular Intensive Care Unit and total hospital), POCD, depressive symptoms between POD 4-10, post-operative complications (infection [surgical site, sepsis, pneumonia], myocardial infarction, renal replacement therapy, re-operation, cumulative opioid consumption (to POD 5), in-hospital mortality.

Post-operative outcomes include POCD (3/6/12 months), depression (3/6/12 months), mild cognitive impairment (MCI) at 3/6/12 months (defined as 1-2 standard deviations below age matched controls), persistent surgical site pain at sternotomy/thoracotomy/graft harvest site (Brief Pain Inventory, 3/6/12 months), recovery (3,6, 12 months).

03

Conditions studied

  • Delirium
  • Cognitive Dysfunction
  • Cognition Disorder
  • Neurocognitive Disorders
  • Mental Disorders
  • Confusion
  • Neurobehavioral Manifestations
  • Neurologic Manifestations
  • Nervous System Diseases
  • Signs and Symptoms
  • Dexmedetomidine
  • Hypnotics and Sedatives
  • Central Nervous System Depressants
  • Physiological Effects of Drugs
  • Analgesics, Non-Narcotic
  • Analgesics
  • Molecular Mechanisms of Pharmacological Action
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned CABG (+/- valve, including off-pump) or valve replacement via sternotomy/thoracotomy, with initial recovery in the Cardiovascular Intensive Care Unit (CVICU)
  • Age ≥60

Exclusion criteria

Exclusion Criteria:

  • Lack of patient consent
  • Pre-operative major cognitive dysfunction (CogState Brief Battery score \< 80) at screening
  • Aortic arch replacement/re-implantation (surgery requiring hypothermic circulatory arrest, e.g. Bentall procedure)
  • Allergy/ to dexmedetomidine (untreated 2nd degree type 2 or 3rd degree heart block (pacemaker), cirrhosis, HR \< 50 , grade 4 LV, renal failure or on renal replacement therapy)
  • Unlikely to comply with study assessments (e.g. no fixed address, cannot complete cognitive tests at the 3, 6, and 12 month time points)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,400 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine Hydrochloride Group

    Patients will receive a loading dose of 1.2 μg/kg dexmedetomidine prior to transfer to CVICU over 20-60 min immediately postoperative, followed by continuous infusion of 0.3 μg/kg/h for up to 12 hours or until patient is ready for discharge from CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.

    Drug: Dexmedetomidine Hydrochloride Group

  • No intervention
    Standard of Care Group

    Standard sedation protocols will be followed at the discretion of the attending physician.

Interventions

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20-60 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.

    Also known as: Dexmedetomidine Hydrochloride

06

What researchers measure

Primary outcomes

  1. Post-operative cognitive dysfunction

    Presence of POCD assessed by CogState Brief Battery (CBB)

    Time frame: 3 months

Secondary outcomes

  1. Post-operative cognitive dysfunction (POCD) at 1 week, 6 months, 12 months after surgery

    POCD assessed by CogState Brief Battery (CBB)

    Time frame: 1 week, 6 and 12 months

  2. Delirium

    Confusion Assessment Method (CAM/CAM-ICU) or Intensive Care Delirium Screening Checklist (ICDSC), binary scale to determine if delirium is present or absent

    Time frame: Anytime up to post-operative day 10

  3. Length of stay

    ICU and total hospital stay

    Time frame: An average of 5 -14 days

  4. Depressive symptoms

    Evaluated by PHQ-9 (Patient Health Questionnaire, scale 0-27, higher score is worse outcome)

    Time frame: 3, 6, and 12 months

  5. Persistent Surgical Site Pain

    Evaluated by Brief Pain Inventory

    Time frame: 3, 6, and 12 months

  6. Quality of Surgical Recovery

    Evaluated by QoR- (Quality of Recovery) 40 questionnaire (scale: 0-200, higher is better outcome)

    Time frame: 3, 6, 12 months

  7. Mild Cognitive Impairment

    Presence of MCI assessed by CogState Brief Battery (CBB)

    Time frame: 3, 6, and 12 months

  8. In-hospital mortality for index surgery

    death before hospital discharge after surgery

    Time frame: through initial inpatient admission, average of 1 week

  9. Opioid consumption to POD 4

    Cumulative opioid consumption

    Time frame: 4 days

  10. Time to extubation

    Time from ICU arrival to cessation of mechanical ventilation

    Time frame: through ICU stay, average of 12 hours

07

Study locations

3 of 8 sites recruiting
08

References and documents

Publications

  • Choi S, Jerath A, Jones P, Avramescu S, Djaiani G, Syed S, Saha T, Kaustov L, Kiss A, D'Aragon F, Hedlin P, Rajamohan R, Couture EJ, Singh A, Mapplebeck JC, Wong S, Orser BA. Cognitive Outcomes after DEXmedetomidine sedation in cardiac surgery: CODEX randomised controlled trial protocol. BMJ Open. 2021 Apr 13;11(4):e046851. doi: 10.1136/bmjopen-2020-046851. PubMed 33849856 ↗

Individual participant data

Plan to share: Yes — All de-identified participants data collected during this trial that underlie the results reported in the publication(s) will be available upon request after publication of the primary results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available upon request immediately after publication of the primary results. No end date.

Access criteria: Direct request to PI. Anyone who wishes to access the data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Jul 2028, 103 months after the start.

Of 40 non-industry phase 4 interventional studies under Delirium, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 62. This study's planned 103 months is above that.

Counting every sponsor, half of 40 studies reached it within 44 months; a quarter within 25 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2019
First posted
Feb 28, 2020
StartActual
Dec 1, 2019
Primary completionEst.
Jul 2028
CompletionEst.
Mar 2029
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04289142
Collaborators
London Health Sciences Centre, University Health Network, Toronto, McMaster University, Canadian Institutes of Health Research (CIHR), The Dana Foundation, Brain Canada, Alzheimer's Association, Hamilton Health Sciences Corporation, University of Saskatchewan, Fraser Health, Providence Health & Services
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Dec 1, 2019
Primary completion
Jul 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Dec 1, 2025

Study contacts

Stephen Choi, MD,MSc,FRCPC
Contact
stephen.choi@sunnybrook.ca
416-480-6100 ext. 1711
Lilia Kaustov, PhD
Contact
lilia.kaustov@sunnybrook.ca
416-480-6100 ext. 89607
Stephen Choi, MD,MSc,FRCPC
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion